Sight Sciences, Inc. (SGHT)

NASDAQ: SGHT · IEX Real-Time Price · USD
4.430
+0.130 (3.02%)
At close: Feb 23, 2024, 4:00 PM
4.400
-0.030 (-0.68%)
After-hours: Feb 23, 2024, 4:23 PM EST
3.02%
Market Cap 215.96M
Revenue (ttm) 82.85M
Net Income (ttm) -61.76M
Shares Out 48.75M
EPS (ttm) -1.27
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 155,532
Open 4.270
Previous Close 4.300
Day's Range 4.240 - 4.505
52-Week Range 1.040 - 11.270
Beta 2.84
Analysts Hold
Price Target 4.60 (+3.84%)
Earnings Date Mar 7, 2024

About SGHT

Sight Sciences, Inc., an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. The company's products include OMNI Surgical System, a therapeutic device used by ophthalmic surgeons to reduce intraocular pressure in adult glaucoma patients; and TearCare System, a wearable eyelid technology for the treatment of dry eye disease (DED) for ophthalmologists and optometrists. It offers its products through sales representatives and distributors to... [Read more]

Industry Medical Devices
Sector Healthcare
IPO Date Jul 15, 2021
Employees 250
Stock Exchange NASDAQ
Ticker Symbol SGHT
Full Company Profile

Financial Performance

In 2022, Sight Sciences's revenue was $71.33 million, an increase of 45.70% compared to the previous year's $48.96 million. Losses were -$86.24 million, 37.0% more than in 2021.

Financial Statements

Analyst Forecast

According to 7 analysts, the average rating for SGHT stock is "Hold." The 12-month stock price forecast is $4.6, which is an increase of 3.84% from the latest price.

Price Target
$4.6
(3.84% upside)
Analyst Consensus: Hold
Stock Forecasts

News

Sight Sciences to Report Fourth Quarter and Full Year 2023 Financial Results on March 7, 2024

MENLO PARK, Calif., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences” or the “Company”), an eyecare technology company focused on developing and commercializing i...

3 days ago - GlobeNewsWire

Sight Sciences Announces European Launch of the Ergo-Series of the OMNI® Surgical System at the ESCRS Winter Meeting

MENLO PARK, Calif., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on developing and commercializing i...

11 days ago - GlobeNewsWire

Sight Sciences Announces the Closing of up to $65 Million Senior Secured Credit Facility with Hercules Capital

MENLO PARK, Calif., Jan. 23, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences”), an eyecare technology company focused on developing and commercializing innovative technol...

4 weeks ago - GlobeNewsWire

Sight Sciences Announces Preliminary, Unaudited Fourth Quarter and Full Year 2023 Financial Highlights

MENLO PARK, Calif., Jan. 08, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on developing and commercializing i...

6 weeks ago - GlobeNewsWire

Sight Sciences Announces Withdrawal of Final LCDs on Micro-Invasive Glaucoma Surgery from Five Medicare Administrative Contractors

Decision ensures continued access to comprehensive outflow procedure enabled by OMNI® Surgical System technology for glaucoma patients Decision ensures continued access to comprehensive outflow proced...

2 months ago - GlobeNewsWire

Sight Sciences Announces the Publication of Successful Results of the SAHARA Randomized Controlled Clinical Trial Comparing TearCare® to Restasis® for the Treatment of Dry Eye Disease

Interventional eyelid procedures enabled by TearCare technology successfully delivered clinically and statistically significant improvements in every sign and symptom measured at every time point thro...

2 months ago - GlobeNewsWire

Sight Sciences Announces the Acceptance for Publication of GEMINI 2, a Three Year, Prospective, Multicenter Trial Demonstrating Sustained, Significant IOP and Medication Reductions Enabled with the OMNI® Surgical System Technology

Prospective, long-term trial results are consistent with the significant body of published clinical evidence demonstrating the durable safety and effectiveness of procedures enabled with the OMNI Surg...

2 months ago - GlobeNewsWire

Sight Sciences Reports Third Quarter 2023 Financial Results and Withdraws Guidance for Full Year 2023

MENLO PARK, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on developing and commercializing i...

3 months ago - GlobeNewsWire

Sight Sciences to Report Third Quarter 2023 Financial Results on November 7, 2023

MENLO PARK, Calif., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences,” or the “Company”), an eyecare technology company focused on developing and commercializing ...

4 months ago - GlobeNewsWire

Sight Sciences to Host SAHARA 6 Month RCT Results Reception at the American Academy of Ophthalmology 2023

The event will include a presentation from Brandon Ayres, MD, Wills Eye Hospital and Sight Sciences executive management team on the successful six month results of the SAHARA head-to head randomized ...

4 months ago - GlobeNewsWire

Sight Sciences Announces Presentation of Successful Phase I Results of the SAHARA Randomized Controlled Clinical Trial Comparing TearCare® to Restasis® for the Treatment of Dry Eye Disease at the American Academy of Optometry Annual Meeting

Interventional eyelid procedures enabled by TearCare technology successfully delivered clinically and statistically significant improvements in every sign and symptom measured at every time point thro...

4 months ago - GlobeNewsWire

Sight Sciences Announces New, Large-Scale MIGS Data from 41st Congress of ESCRS Demonstrating TCOR™ Using OMNI® Surgical System Technology is Effective at Lowering Both IOP and IOP Reducing Medications at 2 Years in Patients with Glaucoma

Efficacy of the Three Most Commonly Used MIGS Technologies plus Cataract Surgery and Cataract Surgery Alone Were Evaluated and Compared in over 100,000 Glaucoma Patient Eyes Efficacy of the Three Most...

5 months ago - GlobeNewsWire

Top 4 Health Care Stocks That Could Lead To Your Biggest Gains In Q3

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Other symbols: SCLXTNYATSBX
5 months ago - Benzinga

Sight Sciences' stock tumbled 32% premarket after revenue warning

Sight Sciences Inc.'s stock SGHT, +6.03% tumbled 32% premarket Tuesday, after the eyecare technology company issued a revenue warning, saying it's seen fewer Surgical Glaucoma new accounts in the thir...

5 months ago - Market Watch

Sight Sciences Provides Revenue Guidance for the Third Quarter of 2023 and Updates Revenue Guidance for Full Year 2023

MENLO PARK, Calif., Sept. 11, 2023 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences,” or the “Company”), an eyecare technology company focused on developing and commercializing...

5 months ago - GlobeNewsWire

Sight Sciences Appoints Matt Link as Chief Commercial Officer

Former NuVasive President helped scale high growth medical device company to over $1 billion in revenue Former NuVasive President helped scale high growth medical device company to over $1 billion in ...

5 months ago - GlobeNewsWire

Sight Sciences to Present at the Upcoming Morgan Stanley 21st Annual Global Healthcare Conference

MENLO PARK, Calif., Aug. 30, 2023 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences,” or the “Company”), an eyecare technology company focused on developing and commercializing ...

6 months ago - GlobeNewsWire

Sight Sciences Reports Second Quarter 2023 Financial Results and Reaffirms Guidance for Full Year 2023

MENLO PARK, Calif., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on developing and commercializing i...

7 months ago - GlobeNewsWire

Sight Sciences Announces Positive Results and Primary Endpoint Successfully Met in SAHARA, a Randomized Controlled Clinical Trial Comparing Interventional Eyelid Procedures Enabled by TearCare® Technology to Restasis¹ for the Treatment of Dry Eye

Dry eye has significant negative impact on visual function including reading, driving, workplace productivity, physical functioning, and quality of life, and creates a substantial burden to patients a...

7 months ago - GlobeNewsWire

Cigna Expands Coverage of Glaucoma Surgical Procedures to Include Canaloplasty and Goniotomy (Trabeculotomy)

Cigna has close to 15 million covered lives Cigna's Coverage Policy includes procedures enabled with OMNI ® Surgical System technology as medically necessary and covered MENLO PARK, Calif., June 21, 2...

8 months ago - GlobeNewsWire

Sight Sciences Announces Addition of New Director Catherine Mazzacco

MENLO PARK, Calif., June 09, 2023 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences” or the “Company”), an eyecare technology company focused on creating innovative solutions in...

9 months ago - GlobeNewsWire

Sight Sciences Two Year Multicenter Study Results Show Sustained Reductions in Both Intraocular Pressure (IOP) and Glaucoma Medication Use in Mild-Moderate Primary Open Angle Glaucoma Patients Treated with a Procedure Enabled with the OMNI® Surgical System Technology

Retrospective Clinical Data from Seven US Sites Published in Clinical Ophthalmology Sustained and clinically meaningful IOP reductions observed at 12 months persisted through 24 months Sustained and c...

9 months ago - GlobeNewsWire

Sight Sciences Announces 12-month Results from the First Minimally Invasive Glaucoma Surgery (MIGS) Comparative Analysis of Real-World Data (RWD) from the American Academy of Ophthalmology IRIS® Registry

Patients undergoing procedures enabled with OMNI® Surgical System technology experienced a greater average reduction in IOP-lowering medication usage compared to other MIGS procedures or cataract surg...

10 months ago - GlobeNewsWire

Sight Sciences to Present at the Upcoming Bank of America Securities 2023 Health Care Conference

MENLO PARK, Calif., April 26, 2023 (GLOBE NEWSWIRE) -- Sight Sciences, Inc . (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform care and impro...

10 months ago - GlobeNewsWire

Sight Sciences to Report First Quarter 2023 Financial Results on May 4, 2023

MENLO PARK, Calif., April 20, 2023 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform care and improv...

11 months ago - GlobeNewsWire